Glenmark gets tentative ANDA approval for new generic

February 17, 2016 | Wednesday | News | By BioSpectrum Bureau

Glenmark gets tentative ANDA approval for new generic

Glenmark's Azelaic Acid Gel is the generic version of Bayer Healthcare's Finacea Topical Gel

Glenmark's Azelaic Acid Gel is the generic version of Bayer Healthcare's Finacea Topical Gel

Glenmark Pharmaceuticals USA (Glenmark) has been granted tentative approval by the United States Food and Drug Administration (US FDA) for its Azelaic Acid Gel, 15 percent, the generic version of Finacea Topical Gel, 15 percent of Bayer Healthcare.

Glenmark will market this product upon receiving final approval of its Azelaic Acid Gel, 15 percent ANDA. The patent listed in the Orange Book for Finacea Topical Gel, 15 percent is scheduled to expire on November 18, 2018.

According to IMS Health sales data for the 12 month period ending December 2015, the Finacea market achieved annual sales of approximately $128.0 million.

Glenmark's current portfolio consists of 106 products authorized for distribution in the US marketplace and 62 ANDA's pending approval with the USFDA.

 

Comments

× Your session has expired. Please click here to Sign-in or Sign-up

Have an Account?

Forgot your password?

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy